ICCC
ImmuCell Corporation
ICCC offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over ICCC overall, supported by stronger modeled upside and lower modeled downside.
ICCC Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
ICCC's revenue, profitability, cash flow and balance sheet are all currently healthy.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ICCC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 22x | $4.26 | -58% |
| Current | 54x | $10.22 | — |
| Fair | 83x | $15.70 | +54% |
| Expensive | 809x | $154 | +1403% |
Historical ranges are pointers, not guarantees.
ICCC's PE is 54x, but its earnings don't support one, so it isn't a reliable read right now.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH has the edge over ICCC in the historical PE scenario, which offers more potential upside but is not a forecast.
ICCC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect ICCC's earnings and revenue to decline, with profitability weakening.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
UNH has the edge over ICCC on the outlook, with more favorable earnings and revenue expectations.
ICCC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.19 | -34% |
| Q2 2026 | $0.07 | -68% |
| Q1 2026 | -$0.07 | -$0.03 |
| Q4 2025 | -$0.12 | +$0.14 |
| Q3 2025 | $0.29 | +$0.79 |
| Q2 2025 | $0.22 | +$0.75 |
| Q1 2025 | -$0.04 | +$0.47 |
| Q4 2024 | -$0.26 | +$0.49 |
ICCC has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
ICCC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8M | +46% |
| Q2 2026 | $7.2M | +12% |
| Q1 2026 | $10.4M | +28% |
| Q4 2025 | $7.6M | -1.6% |
| Q3 2025 | $5.5M | -8.4% |
| Q2 2025 | $6.4M | +18% |
| Q1 2025 | $8.1M | +11% |
| Q4 2024 | $7.8M | +52% |
ICCC's revenue is growing: $8M last quarter, up 46% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | +12 points |
| Q2 2026 | 27% | +18 points |
| Q1 2026 | 19% | +5.2 points |
| Q4 2025 | -0.8% | -8.8 points |
| Q3 2025 | 0.4% | +9.9 points |
| Q2 2025 | 8.8% | +34 points |
| Q1 2025 | 14% | +18 points |
| Q4 2024 | 8% | +28 points |
ICCC has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
ICCC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$589.4K | +$1.2M |
| Q2 2026 | $2.3M | +58% |
| Q1 2026 | $3.4M | +173% |
| Q4 2025 | $310.2K | +$509.5K |
| Q3 2025 | -$1.8M | -$1M |
| Q2 2025 | $1.4M | +207% |
| Q1 2025 | $1.2M | +258% |
| Q4 2024 | -$199.3K | +$605.1K |
ICCC has the edge over UNH on cash flow, with more consistent year-over-year improvement.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
ICCC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +108K shares |
| 1 year | +2.8% | +252K shares |
| 3 years | +20% | +1.6M shares |
| 5 years | +19% | +1.5M shares |
| Available history | +36% | +2.5M shares |
ICCC has 9M diluted shares, up 2.8% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ICCC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ICCC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.0x | Very low |
| Q2 2026 | -0.1x | Net Cash |
| Q1 2026 | 0.4x | Very low |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 6.5x | High |
ICCC has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ICCC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 34.9 | Neutral |
ICCC's weekly RSI is 56 (neutral) and its Stochastic is 35 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ICCC PE vs Healthcare Sector
| Metric | ICCC | Sector median | Relative |
|---|---|---|---|
| PE | 54x | 26x | 108% above |
| PE % | 36 | 29 | 7 pts above |
ICCC is trading at 54x earnings, a 108% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH has the edge over ICCC on valuation relative to its sector.
ICCC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.1 | 1.2% above |
| 20 week MA | $10.3 | 0.8% below |
| 50 week MA | $8.54 | 20% above |
| 100 week MA | $7.15 | 43% above |
| 200 week MA | $6.02 | 70% above |
ICCC's trend is mixed: it's above four of its five weekly moving averages, and 70% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
ICCC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.90 | $6.25 | +28% |
| 2021 | $6.25 | $8.31 | +33% |
| 2022 | $8.31 | $6.23 | -25% |
| 2023 | $6.23 | $5.09 | -18% |
| 2024 | $5.09 | $4.98 | -2.2% |
| 2025 | $4.98 | $6.12 | +23% |
| 2026 YTD | $6.12 | $10.2 | +67% |
ICCC has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.